ResMed Inc. Earnings Recaps
Q3 2026
May 3, 2026
Shares fell 3.3% post-earnings, with investor concerns likely centered on the CFO transition rather than the operational results themselves. The retirement of long-tenured CFO Brett Sandercock and the appointment of Aaron Blumer appears to have overshadowed double-digit revenue and EPS growth.
Key takeaways
- Q3 revenue increased 11% year over year (8% in constant currency).
- Non-GAAP EPS grew 21% from the prior year.
- Gross margin expanded 290 basis points year over year, and 50 basis points sequentially.
- Longstanding CFO Brett Sandercock announced retirement; Aaron Blumer, former Exact Sciences CFO, appointed as successor.
- Product innovation continued, with strong adoption of fabric-based masks and expansion of the AirSense 11 platform into new international markets.
Q2 2026
Jan 30, 2026
ResMed achieved strong second-quarter results for fiscal year 2026, marked by 11% revenue growth and significant margin expansion, driven by innovation in digital health solutions.
Key takeaways
- Revenue increased by 11%, with 9% growth on a constant currency basis, reflecting robust demand across product categories.
- Operating margin improved by 310 basis points year-over-year, with GAAP EPS rising by 16%.
- Global devices revenue grew high single-digits, while masks and accessories experienced double-digit growth, aided by strategic market initiatives.
- Successful launch of new fabric masks enhances ResMed's competitive edge in the market.
- Continued strong cash flow and a solid balance sheet position the company well for future growth and shareholder returns.